Strides Pharma Science Ltd (STAR)

📊 Quarterly Results (₹ Cr)

Revenue has shown sequential stability with a slight decline in Q3 FY26 (₹1,221 crores) followed by a rebound in Q1 FY27 (₹1,265 crores), indicating demand resilience in international markets. Operating margins remain steady around 14-15%, supported by cost discipline despite external cost pressures. Net profit trends reflect both operational performance and non-recurring gains — ₹1,231 crores operational PAT in Q1 FY27 underscores underlying strength, while the spike in reported PAT is attributable to the ₹208 crore stake sale gain. The company has consistently reduced net debt, signaling proactive deleveraging and improved financial flexibility.

🔮 Management Outlook & What's Next

Management maintains a positive long-term outlook, citing sustained growth in Ex-US markets and a pipeline of new product approvals in H2 FY27 to drive future revenue, especially in controlled substances and specialty formats. They are targeting $375 million in North America revenue by FY28, underpinned by strategic expansion and product innovation. Despite geopolitical cost headwinds, management emphasized ongoing cost optimization initiatives and operational efficiency as key levers to protect margins and support scalable growth.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet reflects a conservative and improving financial position, with net debt declining by ₹119 crores to ₹14,246 crores in Q1 FY27, enhancing the Net Debt/EBITDA ratio to 1.52x. Equity remains stable at ₹92 crores, while reserves have grown to ₹3,015 crores as of March 2026, indicating retained earnings and capitalization of surplus. Borrowings have slightly decreased, suggesting effective debt management. The company maintains sufficient liquidity and asset coverage, with total assets growing to ₹6,927 crores, supporting its expansion ambitions without over-leverage.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Institutional investor interest remains strong, with FII holding increasing to 28.39% in Q1 FY27 from 28.51% in Q2 FY26, indicating sustained accumulation. DII holdings have risen steadily from 12.99% in Q2 FY26 to 15.41% in Q1 FY27, reflecting growing confidence among domestic institutional investors. The number of shareholders has also expanded to 94,856 in Q1 FY27 from 85,589 in Q3 FY26, suggesting broader retail participation. Promoter holding remains stable at 27.91%, with no signs of dilution or stake reduction, supporting governance continuity.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Geopolitical and freight cost pressures continue to impact EBITDA margins, as highlighted in management commentary, posing downside risk to profitability despite cost optimization efforts. 2. Dependence on international markets, particularly the US and Ex-US regions, exposes the company to regulatory, currency, and geopolitical volatility. 3. The one-time ₹208 crore gain from the Pivot Path stake sale inflated reported PAT, raising concerns about sustainability of profit growth without similar transactions. 4. Product recall provisions of ₹174.62 million in Q3 FY26 indicate potential quality control or regulatory risks in manufacturing operations, which could affect reputation and future filings.

📋 Recent Filings

• Announcement2026-09-24Strides Pharma Science Limited has announced that its trading window will close on October 1, 2026, and remain shut for 48 hours after the upcoming qu…
• 🟡 sustainability report2026-09-23Strides Pharma Science Limited released its FY26 Sustainability Report, detailing ESG performance across environmental stewardship, social impact, and…
• 🔴 Announcement2026-09-11Strides Pharma Science announced that the USFDA completed a cGMP inspection at its Alathur formulations facility from September 2 to 11, 2026, issuing…
• Announcement2026-08-19Strides Pharma Science announced that its Bengaluru flagship manufacturing facility received a USFDA Establishment Inspection Report (EIR) closing a M…
• 🟡 Board Meeting2026-08-18Strides Pharma Science Limited held its 35th Annual General Meeting on August 14, 2026 via video conferencing, where shareholders approved all four ke…
• 🔴 Financial Results2026-07-31Strides Pharma reported Q1 FY27 revenue of **₹12,654 crores**, up 13% YoY, driven by 17% growth in Ex-US markets. EBITDA rose 5.4% YoY to **₹2,298 cro…
• 🟡 Board Meeting2026-07-31The Board approved unaudited consolidated results for Q3 FY2026 (ended June 30, 2026), showing revenue of **₹12,702.97 crores** and profit after tax o…
• 🔴 Financial Results2026-07-31Strides Pharma Science reported Q1FY27 revenue of **₹12,654m**, up 13% YoY, driven by 17% growth in Ex-US markets, while EBITDA rose 5.4% to ₹2,298m d…
• 🔴 Financial Results2026-07-24Strides Pharma Science Limited announced an earnings call on July 31, 2026 at 17:00 IST to discuss unaudited financial results for the quarter ended J…
• 🟡 sustainability report2026-07-21Strides Pharma Science Limited submitted its Business Responsibility & Sustainability Report (BRSR) for FY25-26 on July 21, 2026, detailing ESG perfor…

🧠 Analyst's Read

Strides Pharma is executing a disciplined growth strategy with improving financial metrics and expanding global footprint, supported by strong institutional interest and prudent capital management. The key watchpoints are execution of new product launches in H2 FY27 and ability to sustain margin resilience amid cost pressures. While near-term growth is evident, long-term value creation will depend on scalable commercialization in high-barrier markets like North America and controlled substances.

Based on filing content and financial data. Not a recommendation.